RX
RXST.US Rxsight Inc
- Market cap
- USD 222M
- P/E
- -
- P/B
- 0.88x
- ROE
- -23.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RXST.US undervalued?
Graham numberThe Graham number of Rxsight Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rxsight Inc fundamental analysis
No fundamental analysis for Rxsight Inc yet.
Rxsight Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that chan…
Full company profileRxsight Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rxsight Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2.24M | 14.7M | 22.6M | 49.0M | 89.1M | 140M | 134M | 119M |
| Gross Profit | -1.82M | 1.71M | 4.52M | 21.3M | 53.8M | 98.9M | 103M | 90.0M |
| Operating Income | -46.1M | -35.4M | -52.8M | -63.3M | -50.1M | -36.9M | -48.2M | -66.8M |
| EBITDA | 130M | 32.2M | -41.0M | -57.8M | -41.0M | -23.8M | -35.6M | -55.1M |
| Net Income | 126M | 27.6M | -48.7M | -66.8M | -48.6M | -27.5M | -38.9M | -58.9M |
| EPS | 6.62 | 1.45 | -1.78 | -2.41 | -1.41 | -0.71 | -0.95 | -1.41 |
| Balance Sheet | ||||||||
| Total Assets | 110M | 101M | 193M | 150M | 183M | 319M | 312M | 340M |
| Total Liabilities | 415M | 398M | 54.5M | 60.3M | 22.2M | 37.3M | 36.1M | 85.5M |
| Shareholders' Equity | -305M | -298M | 138M | 89.9M | 160M | 281M | 276M | 255M |
| Cash & Short-term Investments | 80.7M | 69.0M | 159M | 106M | 127M | 237M | 228M | 255M |
| Total Debt | 5.52M | 30.8M | 44.9M | 45.0M | 3.01M | 12.3M | 11.0M | 10.3M |
| Cash Flow | ||||||||
| Operating Cash Flow | -40.6M | -35.2M | -44.7M | -58.9M | -41.6M | -16.9M | -15.5M | 33.0M |
| Capital Expenditure | 4.09M | 2.54M | 1.94M | 2.39M | 4.81M | 5.44M | 3.83M | 5.19M |
| Free Cash Flow | -44.7M | -37.7M | -46.6M | -61.2M | -46.4M | -22.4M | -19.3M | 27.9M |
| Ratios | ||||||||
| ROE | - | - | -35.2% | -74.3% | -30.3% | -9.8% | -14.1% | -23.1% |
| ROA | 114.3% | 27.4% | -25.3% | -44.5% | -26.6% | -8.6% | -12.5% | -17.3% |
| Net Profit Margin | 5,632.3% | 187.9% | -215.5% | -136.2% | -54.6% | -19.6% | -29.0% | -49.5% |
| Debt to Equity | - | - | 0.33x | 0.50x | 0.02x | 0.04x | 0.04x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rxsight Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 643K | 0.02 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Rxsight Inc
- Insiders 6.52%
- Institutions 88.08%
- Public & others 5.41%
- Shares outstanding 41.9M
- Free float 34.9M
Top funds holding RXST.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.23M | 2.93% | 0.00% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.03M | 2.46% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.01M | 2.40% | 0.00% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 646K | 1.54% | +5.57% | Sep 2026 |
| Bridge Builder Small Cap Fund | 484K | 1.16% | +85.04% | Oct 2026 |
| Fidelity Small Cap Index | 451K | 1.07% | +3.92% | Aug 2026 |
| iShares Russell 2000 Value ETF | 387K | 0.92% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 231K | 0.55% | +0.50% | Sep 2026 |
| Federated Hermes MDT Small Cap Growth IS | 216K | 0.51% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 199K | 0.47% | +0.23% | Oct 2026 |
| Grandeur Peak Global Opportunities Instl | 193K | 0.46% | +34.07% | Jul 2026 |
| Grandeur Peak Global Contrarian Instl | 165K | 0.39% | -10.22% | Jul 2026 |
| BlackRock Advantage Small Cap Gr Instl | 146K | 0.35% | -5.97% | Sep 2026 |
| Fidelity Extended Market Index | 146K | 0.35% | -27.04% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 142K | 0.34% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 135K | 0.32% | -2.30% | Sep 2026 |
| North Square Dynamic Small Cap I | 122K | 0.29% | +60.11% | Jun 2026 |
| iShares Micro-Cap ETF | 120K | 0.29% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 120K | 0.29% | +0.11% | Sep 2026 |
| BlackRock Advantage SMID Cap Instl | 118K | 0.28% | 0.00% | Sep 2026 |
Top institutions holding RXST.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.79M | 13.81% | +81.68% | Jun 2026 |
| Millennium Management LLC | 3.03M | 7.23% | +47.14% | Jun 2026 |
| No Street GP LP | 2.06M | 4.90% | +2.75% | Jun 2026 |
| Nomura Holdings Inc | 2.00M | 4.77% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 1.99M | 4.73% | +1.30% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.68M | 4.00% | -1.03% | Jun 2026 |
| AQR Capital Management LLC | 1.53M | 3.66% | +141.12% | Jun 2026 |
| Acadian Asset Management LLC | 1.45M | 3.46% | -3.49% | Sep 2026 |
| Federated Hermes Inc | 1.20M | 2.86% | +11.15% | Jun 2026 |
| Two Sigma Investments LLC | 1.15M | 2.74% | -11.78% | Jun 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.13M | 2.70% | 0.00% | Jun 2026 |
| UBS Group AG | 1.02M | 2.42% | +324.32% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 999K | 2.38% | -6.35% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 996K | 2.38% | +7,726.45% | Jun 2026 |
| Geode Capital Management, LLC | 985K | 2.35% | +7.08% | Jun 2026 |
| State Street Corp | 852K | 2.03% | +6.26% | Jun 2026 |
| Point72 Asset Management, L.P. | 778K | 1.86% | +6.13% | Jun 2026 |
| Grandeur Peak Global Advisors, LLC | 722K | 1.72% | +55.17% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 701K | 1.67% | +265.89% | Jun 2026 |
| Citadel Advisors Llc | 701K | 1.67% | -37.36% | Jun 2026 |
Rxsight Inc company profile
- Company name
- Rxsight Inc
- Ticker
- RXST.US
- Exchange
- USA Stocks
- Listed since
- Jul 30, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 461
- Fiscal year end
- December
- Address
- 100 Columbia, Aliso Viejo, CA, United States, 92656
- Phone
- 949 521 7830
- Website
- rxsight.com
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Rxsight Inc management
10- Dr. Ilya Goldshleger Ph.D.Chief Operating Officer · born 1975
- Mr. Eric J. WeinbergChief Business Development Officer · born 1961
- Dr. Ronald M. Kurtz M.D.Chief Medical Officer · born 1963
- Mr. Aziz Mottiwala M.B.A.President, CEO & Director · born 1977
- Mr. Mark WilterdingChief Financial Officer · born 1978
- Mr. Oliver MoravcevicVice President of Investor Relations
- Mr. Jim SchindlerExecutive VP & General Counsel
- Mr. Frank ShieldsExecutive Vice President of Sales & Commercial Strategy
- Ms. Maureen O'ConnellExecutive VP of Clinical & Regulatory Affairs
- Mr. Patrick CullenExecutive VP of Quality & Infrastructure Operations